In clinical trials, Zepbound was shown to enable participants to lose about 20% of their body weight after 18 months, exceeding the nearly 14% weight loss seen with Wegovy.
Novo Nordisk is emphasizing the cardiovascular health benefits of Wegovy, stating it not only aids weight loss but also reduces the risk of major heart events.
Collection
[
|
...
]